Scientific Online Resource System

Journal of the Union of Scientists - Varna. Medicine and Ecology Series

MicroRNAs and cardiac health. Their role as a potential biomarker for heart dysfunction

Kalina Ganeva


MicroRNAs are small non-coding molecules that act as regulators to many physiological and pathological reactions. They have been found to be important for the normal development of the cardiovascular system as well as for many pathological processes such as cardiac hypertrophy, cardiac fibrosis, and remodeling. Their wide distribution in body fluids, stability, and resilience make them particularly suitable for isolation, identification and research. There are many pieces of evidence about the role of certain microRNAs in pathogenesis and progression of cardiac failure (microRNA-1, microRNA-21, microRNA-29, microRNA-150), fibrosis (microRNA-21, microRNA-29) and cardiac remodeling by regulating the expression of target genes. In theory, microRNAs have many of the specificities needed for an ideal biomarker—regulators of many pathological processes, wide distribution in biological fluids, stability, and sustainability. At this stage, data on microRNAs is in the field of research, which is why their use in clinical practice is not yet widespread. However, they stand out as a reliable method with great potential for application, both in diagnosis and in targeted therapy.


microRNAs, cardiogenesis, cardiac remodeling, fibrosis

Full Text


Георгиева Ж. и съавт. Биомаркери при сърдечно-съдови заболявания. От патогенезата до прогнозата; Първо издание; под редакцията на проф. Жанета Георгиева, София, Арбилис 2016.

Cheng Y, Tan N, Yang J et al. A translational study of circulationg cell-free microRNA-1 in acute myocardial infarction, Clin Sci (Lond).2010 Apr 20;119(2):87-95.

Condrat C E, Dana T, Madalina B et al. MiRNAs as biomarkers in disease: latest findings regarding their role in diagnosis and prognosis. Cell. 2020 Jan 23;9(2):276.

Creemers EE, Pinto YM, Molecular mechanism that control interstitial fibrosis in the pressure-overloaded heart. Cardiovasc Res. 2011 Feb 1;89:265-272.

Creemers EE, Wilde AA, Pinto YM. Heart failure: advances through genomics. Nat Rev Genet. 2011 May;12(5):357–362.

Devaux Y, Vausort M, McCann G et al. MicroRNA-150: a novel marker of left ventricular remodeling after acute myocardial infarction. Circ Cardiovasc Genet. 2013 Jun;6(3):290-8.

Duisters R, Anke T, Blanche S et al. MiR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling. Cir Res. 2009 Jan 30;104(2):170-8.

Gao J, Xu W, Wang J et al. The role and molecular mechanism of non-coding RNAs in pathological cardiac remodeling. Int J Mol Sci. 2017 Mar 10;18(3):608.

Jin Y, Ling A, Xiaojun C et al. Maternal circulating exosomal miRNAs as non-invasive biomarkers for the prediction of fetal ventricular septal defect. Front Genet. 2021 Sep 9;12:717208.

Kuhn DE, Nuovo GJ, Martin MM, et al. Human chromosome 21-derived miRNAs are overexpressed in Down syndrome brains and hearts. Biochem Biophys Res Commun. 2008 Jun 6;370(3):473–7.

Latronico MV, Catalucci D, Condorelli G. MicroRNA and cardiac pathologies. Physiol Genomics. 2008 Aug 15;34(3):239–42.

Li J, Cao Y, Ma XJ et al. Roles of miR-1-1 and miR-181c in ventricular septal defect. Int J Cardiol. 2013 Sep 30;168(2):1441-6.

Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993 Dec 3;75(5):843-54.

Nagy O, Barath S, Ujfalusi A. The role of microRNAs in congenital heart disease. EJIFCC. 2019 Jun 24;30(2):165-178.

O’Brien JE, Kibiryeva N, Zhou XG et al. Noncoding RNA expression in myocardium from infants with tetralogy of Fallot. Circ Cardiovasc Genet.2012 Jun;5(3):279-86.

Omran A, Eliman D, Webster KA et al, MicroRNAs: a new piece in the paediatric cardiovascular disease puzzle. Cardiol Young. 2013 Oct;23(5):642-55.

Pulignani S, Andreassi MG. MicroRNAs and congenital heart disease: where are we now? Rev Esp Cardiol (Engl Ed). 2019 Jan;72(1):7-9.

Saini V, Rajni M, Shilpa S et al. Can microRNA become next-generation tools in molecular diagnostics and therapeutics? A systemic review. EGMHG. 2021 Dec;22(1):4.

Saliminejad K, Hamid K, Seyed G. Why have microRNA biomarkers not been translated from bench to clinic? Future Oncol. 2019 Mar;15(8):801-803.

Szafranska-Schwarzbach A, Alex A, Linda L et al. Development of a miRNA-based diagnostic assay for pancreatic ductal adenocarcinoma. Expert Rev Mol Diagn. 2011 Apr;11(3):249-57.

Song Y, Hilda H, Jing G et al. Clinical significance of circulating microRNAs as markers in detecting and predicting congenital heart defects in children. J Transl Med. 2018 Feb 27 27;16(1):42.

Souders CA, Bowers SL, Baudino TA. Cardiac fibroblast: the renaissance cell. Circ Res. 2009 Dec 4;105(12):1164–76.

Thum T, Gross C, Fiedler J et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature. 2008 Dec 18;456(7224):980–4.

Tijsen AJ, Pinto YM, Creemers EE. Non-cardiomyocyte microRNAs in heart failure. Cardiovasc Res. 2012 Mar 15; 93(4): 573–82.

Zhao Y., Samal E, Srivastava D. Serum response factor regulates a muscle-specific microRNA that targets Hand2 during cardiogenesis. Nature. 2005 Jul 14:436(7048):214-20.

Zhu S, Cao L, Zhu J et al. Identification of maternal serum microRNAs as novel non-invasive biomarker for prenatal detection of fetal congenital heart defects. Clinica Chim Acta. 2013 Sep 23;424:66-72.

Van Rooij E, Sutherland LB, Thatcher JE et al. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci USA 2008 Sep 2;105(35):13027–32.



Font Size